Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms
© 2023 by The American Society of Hematology..
Peripheral T-cell lymphomas (PTCLs), especially angioimmunoblastic and follicular TCLs, have a dismal prognosis because of the lack of efficient therapies, and patients' symptoms are often dominated by an inflammatory phenotype, including fever, night sweats, weight loss, and skin rash. In this study, we investigated the role of inflammatory granulocytes and activated cytokine signaling on T-cell follicular helper-type PTCL (TFH-PTCL) disease progression and symptoms. We showed that ITK-SYK-driven murine PTCLs and primary human TFH-PTCL xenografts both induced inflammation in mice, including murine neutrophil expansion and massive cytokine release. Granulocyte/lymphoma interactions were mediated by positive autoregulatory cytokine loops involving interferon gamma (CD4+ malignant T cells) and interleukin 6 (IL-6; activated granulocytes), ultimately inducing broad JAK activation (JAK1/2/3 and TYK2) in both cell types. Inflammatory granulocyte depletion via antibodies (Ly6G), genetic granulocyte depletion (LyzM-Cre/MCL1flox/flox), or IL-6 deletion within microenvironmental cells blocked inflammatory symptoms, reduced lymphoma infiltration, and enhanced mouse survival. Furthermore, unselective JAK inhibitors (ruxolitinib) inhibited both TCL progression and granulocyte activation in various PTCL mouse models. Our results support the important role of granulocyte-driven inflammation, cytokine-induced granulocyte/CD4+ TCL interactions, and an intact JAK/STAT signaling pathway for TFH-PTCL development and also support broad JAK inhibition as an effective treatment strategy in early disease stages.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:141 |
|---|---|
| Enthalten in: |
Blood - 141(2023), 23 vom: 08. Juni, Seite 2824-2840 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jaeger, Amelie [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Interleukin-6 |
|---|
| Anmerkungen: |
Date Completed 12.06.2023 Date Revised 08.01.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1182/blood.2022015653 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352071648 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352071648 | ||
| 003 | DE-627 | ||
| 005 | 20240114232908.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/blood.2022015653 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1253.xml |
| 035 | |a (DE-627)NLM352071648 | ||
| 035 | |a (NLM)36696631 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jaeger, Amelie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.06.2023 | ||
| 500 | |a Date Revised 08.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 by The American Society of Hematology. | ||
| 520 | |a Peripheral T-cell lymphomas (PTCLs), especially angioimmunoblastic and follicular TCLs, have a dismal prognosis because of the lack of efficient therapies, and patients' symptoms are often dominated by an inflammatory phenotype, including fever, night sweats, weight loss, and skin rash. In this study, we investigated the role of inflammatory granulocytes and activated cytokine signaling on T-cell follicular helper-type PTCL (TFH-PTCL) disease progression and symptoms. We showed that ITK-SYK-driven murine PTCLs and primary human TFH-PTCL xenografts both induced inflammation in mice, including murine neutrophil expansion and massive cytokine release. Granulocyte/lymphoma interactions were mediated by positive autoregulatory cytokine loops involving interferon gamma (CD4+ malignant T cells) and interleukin 6 (IL-6; activated granulocytes), ultimately inducing broad JAK activation (JAK1/2/3 and TYK2) in both cell types. Inflammatory granulocyte depletion via antibodies (Ly6G), genetic granulocyte depletion (LyzM-Cre/MCL1flox/flox), or IL-6 deletion within microenvironmental cells blocked inflammatory symptoms, reduced lymphoma infiltration, and enhanced mouse survival. Furthermore, unselective JAK inhibitors (ruxolitinib) inhibited both TCL progression and granulocyte activation in various PTCL mouse models. Our results support the important role of granulocyte-driven inflammation, cytokine-induced granulocyte/CD4+ TCL interactions, and an intact JAK/STAT signaling pathway for TFH-PTCL development and also support broad JAK inhibition as an effective treatment strategy in early disease stages | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 700 | 1 | |a Gambheer, Sudheer Madan Mohan |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Xiaoyang |e verfasserin |4 aut | |
| 700 | 1 | |a Chernyakov, Dmitry |e verfasserin |4 aut | |
| 700 | 1 | |a Skorobohatko, Oleksandra |e verfasserin |4 aut | |
| 700 | 1 | |a Mack, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Kissel, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Pfeifer, Dietmar |e verfasserin |4 aut | |
| 700 | 1 | |a Zeiser, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Fisch, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Andrieux, Geoffroy |e verfasserin |4 aut | |
| 700 | 1 | |a Bräuer-Hartmann, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Bauer, Marcus |e verfasserin |4 aut | |
| 700 | 1 | |a Schulze, Susann |e verfasserin |4 aut | |
| 700 | 1 | |a Follo, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Boerries, Melanie |e verfasserin |4 aut | |
| 700 | 1 | |a von Bubnoff, Nikolas |e verfasserin |4 aut | |
| 700 | 1 | |a Miething, Cornelius |e verfasserin |4 aut | |
| 700 | 1 | |a Hidalgo, Jose Villacorta |e verfasserin |4 aut | |
| 700 | 1 | |a Klein, Claudius |e verfasserin |4 aut | |
| 700 | 1 | |a Weber, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Wickenhauser, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Binder, Mascha |e verfasserin |4 aut | |
| 700 | 1 | |a Dierks, Christine |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood |d 1946 |g 141(2023), 23 vom: 08. Juni, Seite 2824-2840 |w (DE-627)NLM000014761 |x 1528-0020 |7 nnns |
| 773 | 1 | 8 | |g volume:141 |g year:2023 |g number:23 |g day:08 |g month:06 |g pages:2824-2840 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1182/blood.2022015653 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 141 |j 2023 |e 23 |b 08 |c 06 |h 2824-2840 | ||